CurveBeam AI Signs Transformational China Partnership to Accelerate Global Expansion

CurveBeam AI (ASX: CVB) has taken a significant step in its global growth strategy, securing a ten-year agreement with a Chinese joint venture that paves the way for the commercialisation of its medical imaging and AI technologies in greater China.

The agreement, finalised with Shandong WeiYing Intelligent Medical Technology Co., gives CurveBeam AI exclusive access to the vast Chinese medical device market including China, Hong Kong, Macau and Taiwan. Under the deal, CurveBeam will receive upfront payments, milestone-linked investments, and royalties on future product sales.

The partnership grants exclusive rights for sales, distribution, manufacturing and regulatory approvals across the region for CurveBeam’s proprietary weight bearing CT (WBCT) scanners and AI-based clinical assessment software. The deal is structured to ensure local manufacturing and regulatory alignment while maintaining global quality standards.

The joint venture partner, backed by Shandong Weigao Haixing Medical Device Co., is an established player in the Chinese orthopaedic device and surgical robotics market. CurveBeam AI will receive an equity investment of up to 10 million Australian dollars, with an initial 4 million dollar payment expected within the next 60 days. The remaining 6 million dollars will be tied to commercial and regulatory milestones, with shares issued at 40.5 cents each.

CurveBeam CEO Greg Brown described the agreement as a pivotal milestone. “Partnering with an established Chinese medical device manufacturer and distributor positions us to significantly accelerate adoption of our platforms and AI solutions across China and the entire globe,” Brown said.

Key agreements include intellectual property licensing, manufacturing and distribution rights, and a share subscription arrangement. All shares issued under the agreement will be subject to a 24-month voluntary escrow, aligning both parties with long-term growth objectives.

In addition to facilitating access to the world’s second largest medical device market, the deal provides CurveBeam with manufacturing scale, supply chain resilience and cost optimisation benefits. Devices produced locally in China will also be eligible for government-backed procurement schemes, providing a pathway to broader adoption.

The partnership is governed by a joint steering committee with equal representation and includes strict non-compete clauses. Regulatory responsibilities will be shared, with CurveBeam overseeing approvals for US-manufactured devices, and the Chinese partner handling locally produced units.

The agreement supports CurveBeam’s ambition to expand its global footprint while driving sustained revenue growth through product sales and long-term royalty streams. It also allows the company to mitigate tariff risks and accelerate innovation through closer collaboration with its new partner.

With China’s imaging device market comprising more than 38,000 hospital sites, the strategic significance of this partnership cannot be overstated. CurveBeam AI is now positioned to fast-track its next generation technologies and extend its leadership in AI-enabled musculoskeletal imaging solutions.